The impact of interacting drugs on dispensed doses of warfarin in the swedish population: A novel use of population based drug registers

Journal of Clinical Pharmacology

Volumn 53, Issue 12, 2013, Pages 1322-1327

  Andersson, M L ^a   Lindh, J D ^a   Mannheimer, B ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Drug interactions; Drug prescription; Retrospective study; Warfarin

Indexed keywords

BEZAFIBRATE; CARBAMAZEPINE; LACTULOSE; WARFARIN;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG INTERACTION; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; REGISTER; RETROSPECTIVE STUDY; SWEDEN;

DRUG INTERACTIONS; DRUG PRESCRIPTION; RETROSPECTIVE STUDY; WARFARIN;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; SWEDEN; WARFARIN; YOUNG ADULT;

EID: 84893025892     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.174     Document Type: Article

References (35)

1. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. Br Med J. 2002;325:828-831.
2. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarintreated cohort supports genetic forecasting. Blood. 2009;113:784-792.
3. Rasmussen MA, Skov J, Bladbjerg EM, Sidelmann JJ, Vamosi M, Jespersen J. Multivariate analysis of the relation between diet and warfarin dose. Eur J Clin Pharmacol. 2012;68:321-328.
4. SFINX, Swedish Finnish Interaction Xreferencing, cited 201303 http://www.janusinfo.se.
5. Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis. 2008;25:151-159.
6. Jonsson AK, Spigset O, Jacobsson I, Hagg S. Cerebral haemorrhage induced by warfarin - The influence of drug-drug interactions. Pharmacoepidemiol Drug Saf. 2007;16:309-315.
7. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register - Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726-735.
8. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106:86-94.
9. WHOGuidelines for ATC classification and DDD assignment 2008. Cited December 2011 http://www.whocc.no.
10. Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von BC, Eliasson E. Nationwide drugdispensing data reveal important differences in adherence to drug label recommendations on CYP2D6dependent drug interactions. Br J Clin Pharmacol. 2010;69:411-417.
11. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-1658.
12. Gurwitz JH, Avorn J, RossDegnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992;116:901-904.
13. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45:704-706.
14. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics. 2004;14:539- 547.
15. Absher RK, Moore ME, Parker MH. Patientspecific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36:1512-1517.
16. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarinfluconazole. I. Inhibition of the human cytochrome P450dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab Dispos. 1996;24:414-421.
17. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: Dosing relationships with longterm therapy. Chest. 2002;121:19-23.
18. McDonald MG, Au NT, Wittkowsky AK, Rettie AE. Warfarinamiodarone drugdrug interactions: Determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clin Pharmacol Ther. 2012;91:709-717.
19. Ahmed A, Stephens JC, Kaus CA, Fay WP. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprimsulfamethoxazole or levofloxacin. J Thromb Thrombolysis. 2008;26:44-48.
20. Hickmott H, Wynne H, Kamali F. The effect of simvastatin comedication on warfarin anticoagulation response and dose requirements. Thromb Haemost. 2003;89:949-950.
21. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost. 2006;4:1422-1424.
22. Mahe I, Bertrand N, Drouet L, et al. A haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol. 2005;59:371-374.
23. Kendall AG, Boivin M. Warfarincarbamazepine interaction. Ann Intern Med. 1981;94:280.
24. Hansen JM, SiersboekNielsen K, Skovsted L. Carbamazepineinduced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther. 1971;12:539-543.
25. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarincarbamazepine interaction. South Med J. 1990;83:981.
26. Massey EW. Effect of carbamazepine on Coumadin metabolism. Ann Neurol. 1983;13:691-692.
27. Herman D, Locatelli I, Grabnar I, et al. The influence of cotreatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol. 2006;62:291-296.
28. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: An update. Clin Pharmacokinet. 1996;31:198-214.
29. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999;24:87-92.
30. Bezalip (bezafibrate) SPC. Actavis. Cited 20130325. SPC, 2013. Ref Type: Electronic Citation.
31. Beringer TR. Warfarin potentiation with bezafibrate. Postgrad Med J. 1997;73:657-658.
32. AlMomen AK, AlAbdulKareem H. Potentiation of the action of warfarin by bezafibrate in patients with the nephrotic syndrome. Saudi J Kidney Dis Transpl. 1994;5:12-16.
33. Dobrzanski S, Duncan SE, Harkiss A, Wardlaw A. Age and weight as determinants of warfarin requirements. J Clin Hosp Pharm. 1983;8:75-77.
34. Herman D, Locatelli I, Grabnar I, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5:193-202.
35. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-764.